The clinical data significantly de-risks the vopimetostat + daraxonrasib combination in PDAC, with an 82% ORR and 88% 9-month PFS rate that appear best-in-class. The FDA-aligned Phase 3 path in 1L PDAC and potential accelerated 2L path create a clear regulatory catalyst. The strategic reprioritization and workforce reduction signal focus and capital discipline. Key catalysts to watch: Phase 3 initiation in 1H 2027, January 2027 monotherapy data readouts, and any partnership/supply agreements for daraxonrasib.
Price Chart
Executive Summary
Tango Therapeutics reported highly promising Phase 1/2 data for vopimetostat + daraxonrasib in MTAP-deleted PDAC, showing an 82% ORR and 88% 9-month PFS rate in heavily pretreated patients. The company also announced a strategic reprioritization, including a ~14% workforce reduction, to focus on PRMT5-targeted therapies, and plans to initiate a Phase 3 registrational trial in 1L PDAC in 1H 2027 following FDA discussions.
Key Facts
- 82% ORR (18/22) in 2L/3L MTAP-deleted/RAS-mutant PDAC patients treated with vopimetostat + daraxonrasib; median PFS not yet reached; 88% 9-month PFS rate
- 100% disease control rate in PDAC; all unconfirmed responses subsequently confirmed after data cutoff
- No dose-limiting toxicities, no withdrawals due to TRAEs, and no Grade 4/5 TRAEs at dose level 1 in PDAC
- 54% ORR (19/35) with vopimetostat + zoldonrasib in KRAS G12D MTAP-deleted PDAC; 61% 9-month PFS rate
- Planned global randomized Phase 3 trial of vopimetostat + daraxonrasib vs SOC chemo in 1L MTAP-deleted PDAC (N=484, dual primary ORR and PFS) expected to start 1H 2027
- Board approved strategic reprioritization to focus on PRMT5-targeted therapies; ~14% workforce reduction, primarily from research group
- $1.0B cash and investments as of June 30, 2026, expected to support PDAC late-stage development
- Company expects to report vopimetostat monotherapy NSCLC data and TNG456 monotherapy data in January 2027
Financial Impact
No revenue or earnings reported; $1.0B cash runway supports late-stage development; workforce reduction of ~14% indicates cost optimization
Risk Factors
- Phase 3 trial may fail to replicate Phase 1/2 results in a larger, randomized setting
- Dependence on Revolution Medicines for daraxonrasib clinical supply; no supply agreement yet disclosed
- Dose level 2 showed poor tolerability (3 DLTs in 2 patients), limiting dose flexibility
- Workforce reduction may slow early-stage pipeline progress despite focus on PRMT5 programs
- Competitive landscape includes other PRMT5 inhibitors and RAS-targeted therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-429423 |
| Document: d151613dex992.htm | 0001193125-26-429423 |
| Document: d151613dex991.htm | 0001193125-26-429423 |
| Document: 0001193125-26-429423-index-headers.html | 0001193125-26-429423 |
| Document: 0001193125-26-429423-index.html | 0001193125-26-429423 |
| Document: 0001193125-26-429423.txt | 0001193125-26-429423 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $23.34 | awaiting T+60 | — | $22.89 (−1.93%) |
Aug 11, 2026 11w ago | 8-K | $25.58 | awaiting T+60 | — | $22.89 (+10.52%) |
Aug 11, 2026 11w ago | 8-K | $26.34 | awaiting T+60 | — | $22.89 (−13.10%) |
Aug 11, 2026 11w ago | Press Release | $26.34 | awaiting T+60 | — | $22.89 (−13.10%) |
Aug 9, 2026 11w ago | Institutional Cluster | $27.67 | awaiting T+60 | — | $22.89 (−17.28%) |
Aug 6, 2026 11w ago | 8-K | $27.07 | awaiting T+60 | — | $22.89 (−15.44%) |
Jun 11, 2026 19w ago | 144 | $30.94 $24.00 | ▼ −22.43% | ▼ −25.21% | $22.89 (−26.02%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.82 $22.70 | ▼ −23.88% | ▼ −27.70% | $22.89 (−23.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.82 $22.70 | ▼ −23.88% | ▼ −27.70% | $22.89 (−23.24%) |
Jun 10, 2026 19w ago | 424B5 | $29.82 $22.70 | ▼ −23.88% | ▼ −27.70% | $22.89 (−23.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers